Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login


Drug safety

Role for smartphones and social media in medicine safety

An app will be developed to make it easy for healthcare professionals and the public to report suspected adverse drug reactions.

Mobile screen with social media apps

Source: Quka /

The project will look at the potential for identifying drug safety issues via mining of publically available social media data

An app will be developed to make it easy for healthcare professionals and the public to report suspected adverse drug reactions (ADRs) to national and European regulators.

An EU initiative wants to widen the use of smartphones and social media for transmitting notifications about drug safety issues directly to patients, clinicians and caregivers. The three-year project, known as WEB-RADR, involves the Medicines and Healthcare products Regulatory Agency (MHRA). It will investigate the potential of social media data and its value for pharmacovigilance and pharmacoepidemiology.

Funded by the Innovative Medicines Initiative, a public–private partnership between the European Union and the European Federation of Pharmaceutical Industries and Associations, WEB-RADR also aims to come up with recommendations for the medicines regulators and the pharmaceutical industry on how these new approaches can be integrated with existing systems.

A workshop to launch the scheme will be held at the European Medicines Agency at the end of October 2014.

“The growing use of smartphones and tablets by patients and healthcare professionals creates a need for reporting forms to be provided on these platforms to ensure regulators receive ADR reports that are easy to access and complete,” says Mick Foy, from the MHRA’s vigilance and risk management of medicines division.

“[T]he recent growth of social media platforms, such as Facebook, Twitter and the many specialist sites and blogs, has given rise to many people sharing their medical experiences publically on the internet. Such data sharing, if properly harnessed, could provide an extremely valuable source of information for post-marketing surveillance for suspected adverse drug reactions and safety monitoring.”

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2014.20066370

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.